Identifying beneficial gastric cancer patient on prognosis after treating with perioperative or postoperative-only chemotherapy: a single-center real-world study
Real-world data suggest that perioperative SOX chemotherapy does not benefit all patients with advanced gastric cancer. Patients with TRG 2-3, older age, or cT3 stage may achieve better outcomes with postoperative chemotherapy. Additionally, an exploratory analysis indicated that CA125 positivity may be associated with improved survival following adjuvant treatment.
Authors
- Zhiyuan Xu (ORCID: https://orcid.org/0000-0001-6875-7171)
- Weiwei Zhu (ORCID: https://orcid.org/0000-0003-4051-2353)
- Ruolan Zhang
- Qingwu Yang (ORCID: https://orcid.org/0000-0002-2596-2631)
- Siwei Pan (ORCID: https://orcid.org/0000-0002-8027-9341)
- Can Hu (ORCID: https://orcid.org/0000-0002-8687-8310)
- Jiaqing Zhang (ORCID: https://orcid.org/0000-0002-6859-1260)
- Yanqiang Zhang (ORCID: https://orcid.org/0000-0002-9118-9800)
Institutions
- Zhejiang Chinese Medical University (CN)
- Zhejiang Cancer Hospital (CN)
- Cancer Hospital of Chinese Academy of Medical Sciences (CN)
Publication Details
- Journal
- World Journal of Surgical Oncology
- Published
- 2025-05-04
- DOI
- https://doi.org/10.1186/s12957-025-03827-w
- Citations
- 1
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- National Natural Science Foundation of China
- Medical Science and Technology Project of Zhejiang Province
- Science and Technology Program of Zhejiang Province